The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies
Open accessThe DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Abstract
Purpose Pre-clinical and early clinical data suggests the microbiome plays an important role in oncogenesis and influences response to immune checkpoint blockade (ICB). The objective of this systematic review and meta-analysis was to determine whether antibiotics affect overall survival (OS) and progression free survival (PFS) in patients with solid malignancies treated with ICB.Patients and methods A systematic search of EMBASE, MEDLINE and conference proceedings was conducted for observational studies examining the effect of antibiotics on ICB. A random effects study-level meta-analysis was performed with pooling of the hazards ratio (HR) for OS and PFS. Meta-regression was used to determine the impact of the timing of antibiotic exposure on OS.Results 766 studies were identified, and 18 studies met the inclusion criteria. Of the 2889 patients included, 826 (28.6%) were exposed to antibiotics. The most common malignancies were lung (59%), renal cell carcinoma (RCC) or urothelial carcinoma (16.3%) and melanoma (18.7%). OS was prolonged in those without antibiotic exposure (pooled HR 1.92, 95% CI 1.37-2.68, p < 0.001). The effect of antibiotics on OS was greater in studies defining antibiotic exposure as 42 days prior to initiation of ICB (HR 3.43, 95% CI 2.29-5.14, p < 0.0001). PFS was also longer in patients who did not receive antibiotics (pooled HR 1.65, 95% CI 1.3-2.1, p < 0.0001).Conclusion In patients receiving ICB, OS and PFS are longer in patients who are not exposed to antibiotics. Antibiotic use in the 42 days before starting ICB appears to be most detrimental to outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At the same time, retrospective studies have implicated that antibiotics were associated with decreased survival and attenuated response to ICI in patients with advanced solid tumors [39–44], supporting a causal link between antibiotic-induced dysbiosis and poor therapeutic efficacy of ICI.”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Practical methods for incorporating summary time-to-event data into meta-analysis.
Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S., & Sydes, M. R. (2007) · Trials · doi:10.1186/1745-6215-8-16 · Cited by 6,208
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488
Self-citationThe commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Dethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361
Depommier, C., Everard, A., Druart, C., Plovier, H., Van Hul, M., Vieira-Silva, S., Falony, G., Raes, J., Maiter, D., Delzenne, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0495-2 · Cited by 2,357
Research works printed but not linked: 3
- Schett ARS, Mauti LA, Schmid S, Appenzeller C, Curioni-Fontecedro A, Frueh M, Joerger M (2019) Progsnotic impact of the use of antibiotics in patients with advanced non-small cell lung cancer receiving PD-(L)1 targeting monoclonal antibodies. Ann Oncol 30(Supplemental 2):157
- Derosa L, Routy B, Enot D, Fidelle M, Gubet AG, Goldwasser F, Zitvogel L, Loriot Y, Albiges L, Escudier B (2018) Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Kidney Cancer 2(Supplement 1):S24–S25
- Wilson BE, Routy B, Nagrial A, Chin V (2019) The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies. Asia-Pacific J Clin Oncol 15(supplemental 9):359
Cited by
Items 101–151 of 151
Research progress on gut microbiota in colorectal cancer immunotherapy
Li, J., Yue, Y., Pan, J., & Liang, F. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189476 · Cited by 7
Dual immune checkpoint blockade strategies for cancer therapy
Liu, Y., Yadav, U. P., Chen, C., & Wang, P. (2026) · Cell investigation. · doi:10.1016/j.clnves.2026.100064 · Cited by 7
Venneri, T., Giorgini, G., Leblanc, N., Flamand, N., Borrelli, F., Silvestri, C., & Marzo, V. D. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01823-1 · Cited by 6
Precision Targeting of the Gut Microbiome for Cancer Immunotherapy
Lombardi, P., & Pinato, D. J. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0538 · Cited by 5
Die Rolle des Mikrobioms in der Urologie
Magistro, G., Marcon, J., Eismann, L., Volz, Y., & Stief, C. G. (2020) · Der Urologe · doi:10.1007/s00120-020-01368-6 · Cited by 5
Ochi, N., Ichihara, E., Yokoyama, T., Inoue, K., Tamura, T., Watanabe, H., Takata, I., Kano, H., Nakamura, K., Kawai, H., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02860-9 · Cited by 5
Fatty acid in the tumor microenvironment: Perspectives for immunotherapy
Li, T., Bie, Y.-R., Chen, S.-M., Shang, Y., & Hu, P. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104878 · Cited by 5
Antibiotics, the microbiome and gastrointestinal cancers: A causal interference?
Ramai, D., Salati, M., Pomati, G., Amoroso, C., Facciorusso, A., Botticelli, A., & Ghidini, M. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102315 · Cited by 4
Manning‐Bennett, A. T., Cervesi, J., Bandinelli, P.-A., Sorich, M. J., & Hopkins, A. M. (2023) · Biomedicines · doi:10.3390/biomedicines11020528 · Cited by 4
“Antibiotics cause gut dysbiosis and thus hypotheses are that antibiotics may decrease the effectiveness of ICIs—however, evidence of casual impacts on ICI efficacies remains debated [6,7].”
BackgroundLocal Delivery of Immunomodulatory Antibodies for Gastrointestinal Tumors
Silva-Pilipich, N., Covo-Vergara, Á., & Smerdou, C. (2023) · Cancers · doi:10.3390/cancers15082352 · Cited by 5
Chambers, L., Chalif, J., Yao, M., Reizes, O., Rose, P. G., Michener, C. M., & Vargas, R. (2026) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2026.37.e69 · Cited by 3
Kennedy, O. J., Glassée, N., Kiciński, M., Blank, C. U., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113585 · Cited by 3
Smibert, O. C., Vogrin, S., Sinclair, M. J., Majumdar, A., Nasra, M., Pandey, D., Jahanabadi, H., Trubiano, J. A., Markey, K. A., Slavin, M. A., et al. (2025) · Transplant Infectious Disease · doi:10.1111/tid.70026 · Cited by 4
Nagasaka, M., Al-Share, B. A., Shao, Y. F., Sexton, R. E., Hallak, M. N. A., Azmi, A. S., & Sukari, A. W. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00047-4 · Cited by 3
Fidelle, M., Derosa, L., Routy, B., & Zitvogel, L. (2021) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2021.01.022 · Cited by 2
Self-citationRausch, M. P., Moodley, D., Peluso, M. O., Koseoglu, S., Hua, J., Tan, G., Masia, R., Lee, B. H., Cousineau, I., Turcotte, S., et al. (2020) · Regular and Young Investigator Award Abstracts · doi:10.1136/jitc-2020-sitc2020.0727 · Cited by 2
Influence of Intestinal Flora on ICB Therapy for Colorectal Cancer
赵, 飞. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.14123181 · Cited by 2
Hughes, V. S., Vick, E. J., Schwartz, R. N., Jandarov, R., Guo, J. J., Lin, A. C., & Hincapie, A. L. (2025) · JAPhA Pharmacotherapy · doi:10.1016/j.japhar.2025.100012 · Cited by 1
Hori, T., Yamamoto, K., Ito, T., Ikushima, S., Omura, T., & Yano, I. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02859-2 · Cited by 1
Kleinhans, M., Lissen, A., Hewitson, L., & Rijkers, G. T. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2621240 · Cited by 1
“In a more general context, many studies indicate pre-treating ICI patients with antibiotics can have a significant detrimental effect on PFS and OS [28–30].”
Bailey, S. L., Patel, J. D., Havighurst, T. C., Pozorski, V., Mohamoud, Y., Tesfamichae, D., Dow-Hillgartner, E. N., Jung, L., Birbrair, A., & Ma, V. T.-L. (2026) · Immunotherapy · doi:10.1080/1750743x.2026.2626241 · Cited by 1
“Wilson et al. conducted a meta-analysis on all solid tumor types and found overall antibiotic use significantly reduced survival outcomes [16].”
Microbiome‐urothelium crosstalk in bladder cancer: From dysbiosis to clinical translation
Xu, H., Li, Z., Yang, L., Zheng, J., Li, W., Liao, R., Huang, W., Sun, B., Li, Z., Ma, C., et al. (2026) · iMetaOmics. · doi:10.1002/imo2.70081 · Cited by 1
“Specifically, broad ‐ spectrum antibiotics administered prior to ICI initiation significantly reduce overall survival, whereas narrow ‐ spectrum antibiotics show no comparable detrimental effect [182, 183].”
Takada, S., Nasu, I., Uozumi, R., Kondo, M., Nawata, S., Iihara, H., Okumura, Y., Hashishita, H., Takemoto, M., Okada, T., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-46185-7 · Cited by 1
Microbiome as a prediction of immunotherapy response in lung cancer
Rojas, L., Zuluaga, J., & Cardona, A. F. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1849553 · Cited by 1
“The adverse effect is strongest when antibiotics are administered within 30 – 60 days before or after ICI initiation, during immune priming, and early effector response, whereas later antibiotic use shows variable associations (52 – 54).”
Die Rolle des Mikrobioms bei urologischen Erkrankungen
Atzler, M., Westhofen, T., Tamalunas, A. J., Schott, M., Keller, P., Ebner, B., Stief, C. G., & Magistro, G. (2021) · Aktuelle Urologie · doi:10.1055/a-1478-2960 · Cited by 1
“[21] Wilson BE, Routy B, Nagrial A et al.”
BackgroundAdvanced gallbladder cancer with high tumor mutation burden: a case report and literature review
Wang, J., Liu, J., Chao, Y., Wang, K., Li, Q., & Yu, J. (2024) · AME Case Reports · doi:10.21037/acr-23-188 · Cited by 1
“Of note, the heterogeneity in terms of mutational burden and poor prognosis in patients with GBC should be taken into account, as the use of immunotherapies such as ICB can cause hyper-progressive disease (HPD) (37).”
InfluentialImlay, H. N., Greenlee, S. B., Tritle, B. J., Fino, N. F., & Spivak, E. S. (2024) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2024.446 · Cited by 1
Grassi, P., Hilgers, W., Boissier, R., Bertucci, A., Bruyat, D., Duffaud, F., Enoch, F., Rochigneux, P., Mancini, J., & Deville, J. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102283 · Cited by 1
Quoi de neuf en oncodermatologie ?
Montaudié, H. (2020) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/s0151-9638(20)31106-6
Cancer Immunotherapy Clinical Trials
Kwapisz, D. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_205-2
Supplementary Data from Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?
(2023) · doi:10.1158/2159-8290.22540051.v1
Self-citationInfluence of Antibiotic Use on the Effectiveness and Safety of Immune Checkpoint Inhibitors
Minamishima, T., Hida, H., Miyazaki, M., Kon, S., Senzaki, K., Nagai, T., & Yamada, K. (2022) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.48.173
Argoubi, R., Reese, E. S., Furegato, M., Medina, P., & Bobiak, S. N. (2023) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2022-0201
Sarmento, L. A., Assis, G. L. D., Aragão, L. V. F. D., Batista, A. C. G. F., Freire, F. S. F., Moura, G. D. A., de Sá, E. V., Prado, D. S., de Souza, L. M. C. I., Santana, L. E. M., et al. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n5-521
Antibiotic Use and Survival in Patients With Late-Stage NSCLC Treated With Chemoimmunotherapy
Taioli, E., Flores, R. M., Abdelhamid, A., Untalan, M., Ivic‐Pavlicic, T., & Tuminello, S. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100710 · Cited by 3
Immunbedingte Nebenwirkungen: Wie erkennen – wie behandeln?
Arnheim, K. (2024) · Onkologische Welt · doi:10.1055/a-2438-4933
Microbiome and Human Cancer: Descriptive Literature Review
Arutyunyan, D. N., Петрова, В. Д., Терехова, С. А., & Lazarev, A. F. (2024) · Russian Journal of Oncology · doi:10.17816/onco642393
Bührer, E., Glassée, N., Kiciński, M., Kennedy, O. J., Blank, C. U., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., et al. (2025) · EJC Skin Cancer · doi:10.1016/j.ejcskn.2025.100727
Park, S. M., Jeong, J., Kim, Y. J., & Lee, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-05899-w
“Consequently, concurrent use of medications that affect immune function, such as antibiotics, proton pump inhibitors (PPIs), immunosuppressants, and steroids, may alter the efficacy of ICIs and reduce the odds of survival 8–10 .”
Vrana, E., Timmins, H., Osborne, A., Cox, R., Wasan, H. S., Ma, Y. T., Arora, A., Faluyi, O. O., Gillmore, R., Corrie, P. G., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2539018 · Cited by 1
Cancer Immunotherapy Clinical Trials
Kwapisz, D. M. (2025) · Springer eBooks · doi:10.1007/978-3-032-00767-4_205
Zhao, Y., Naidoo, J., Conroy, M. R., Ferri, J. T., Gills, J. J., Chen, K. Y., White, J. R., Glass, S., Assan, W. O., Peloza, K. E., et al. (2025) · medRxiv · doi:10.1101/2025.10.01.25336378
Coschi, C. H., Ding, K., Tu, D., O’Callaghan, C., Leighl, N. B., Vera-Badillo, F., Juergens, R. A., Hao, D., Seymour, L., Renouf, D. J., et al. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2578164
Spakowicz, D. J., Hoyd, R., Muniak, M., Husain, M., Bassett, J. S., Wang, L., Tinoco, G., Patel, S. H., Burkart, J. T., Miah, A., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12262949
Spakowicz, D. J., Hoyd, R., Muniak, M., Husain, M., Bassett, J. S., Wang, L., Tinoco, G., Patel, S. H., Burkart, J. T., Miah, A., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12262943
Kankkunen, E., Sunela, K. L., Makkonen, T. M., Jalkanen, K. J., & Mattila, K. (2026) · Acta Oncologica · doi:10.2340/1651-226x.2026.44974
“Previous studies have shown the potential effect of gut microbiome on the efficacy of immunotherapy [13, 19, 22–24] and the association of ABT with poor outcomes in various cancers treated with ICI [25, 26].”
Cancer-Induced Ileopathy and Dysbiosis Contribute to Carcinogenesis
Yonekura, S. (2020) · theses.fr (ABES) · doi:10.70675/d456a746zde60z4ec9zab97zefec41211866
Rachofsky, C., Liu, M. H., D’Aiello, A., Halmos, B., McLellan, B. N., & Deutsch, A. (2026) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2026.06.046
Joo, M.-K., Tak, J., Ha, S., Yoon, K., Namgoong, J., & Kim, H. O. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1835588
Ishigami, Y., Takahashi, M., Nakatsukasa, H., Shibano, M., Kato, M., Takahashi, K., Uchida, J., Nakamura, Y., & Kaneda, H. (2026) · Immunotherapy · doi:10.1080/1750743x.2026.2702265
Cancer pharmacomicrobiomics: Targeting microbiota to optimize cancer therapy outcomes
Punuri, S. V., Dagar, W., Vodnala, S., Bhyan, B., & Jangra, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33206-7.00011-x
Metadata
- Authors
- Wilson, B. E., Routy, B., Nagrial, A., & Chin, V. T.
- Affiliations
- UNSW Sydney (AU)
- Centre Hospitalier de l’Université de Montréal (CA)
- The University of Sydney (AU)
- Garvan Institute of Medical Research (AU)
- Corresponding author
- Wilson, Brooke E.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2019-12-21
- Volume
- 69
- Issue
- 3
- Pages
- 343-354
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC11027824
- OpenAlex
- W2995658490
- Cited by
- 152
- References
- 57
- Citations by year
- 2026: 13 · 2025: 23 · 2024: 21 · 2023: 26 · 2022: 21 · 2021: 23 · 2020: 24 · 2019: 1
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- antibiotics, immune checkpoint blockade, gut microbiota, overall survival, progression-free survival, solid tumors, lung cancer, renal cell carcinoma, urothelial carcinoma, melanoma, cancer immunotherapy outcomes
- MeSH terms
- Anti-Bacterial Agents, Humans, Immunotherapy, Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.